Growth hormone secretagogue and GHRH analogue research peptides in Canada. Ipamorelin, CJC-1295, Sermorelin, Tesamorelin. Per-lot certificates.
Peptides
GHRH Analogue Research Peptide Tesamorelin is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH). It is developed for controlled laboratory research involving hypothalamic-pituitary signaling systems.
TESA-CA-26F-1098.763%
11.68 mg / 10 mg
$114.95CAD
Peptides
Dual GHRH / GHS-R Research Blend CJC-1295 + Ipamorelin is a dual-peptide research formulation combining a growth hormone–releasing hormone (GHRH) analogue with a selective ghrelin receptor (GHS-R1a) agonist. It is developed for controlled laboratory investigation involving hypothalamic-pituitary signaling systems.
CJC-1295 (mod GRF 1-29) 5.57 mg / Ipamorelin 5.88 mg / 10 mg
$64.95CAD
Peptides
GHRH Analogue Research Peptide CJC-1295 (No DAC) is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH) developed for controlled laboratory research. The “No DAC” designation indicates the absence of a drug affinity complex, resulting in a shorter receptor interaction profile within experimental systems.
10 mgCJND-CA-26F-1099.777%
10.76 mg / 10 mg
$69.95CAD
Peptides
Ghrelin Receptor Research Peptide Ipamorelin is a synthetic peptide developed for controlled laboratory research involving ghrelin receptor signaling systems. It is structurally designed to interact with growth hormone secretagogue receptor (GHS-R1a) pathways within experimental environments.
10 mgIPAM-CA-26G-1099.753%
11.75 mg / 10 mg
$64.95CAD
Peptides
GHRH(1-29) Analogue Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of growth-hormone-releasing hormone, studied in research on the GH/IGF-1 axis.
5 mgSERM-CA-26D-0198.78%
5.56 mg / 5 mg
$54.95CAD
Peptides
Long-Acting GHRH Analogue CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) bearing a Drug Affinity Complex that extends its half-life, studied in research on the GH/IGF-1 axis.
5 mg$44.95CAD
Lot, purity and measured content on every card match the published certificate.
Lyophilized research peptides and blends — BPC-157, TB-500, retatrutide, tirzepatide, ipamorelin, semax — with purity and measured content per lot.
53 products →Metered research sprays of semax, selank, BPC-157, KPV, PT-141 and oxytocin, filled from a tested powder batch.
21 products →Oral-format research compounds pre-measured per capsule, with measured content per lot on the published certificate.
20 products →Khavinson short peptides — epitalon, pinealon, cartalax, vesugen, livagen, crystagen — each matched to one tissue.
20 products →NAD+ and glutathione research vials at 500 mg to 1500 mg, with measured content verified per lot.
2 products →GHK-Cu and AHK-Cu copper peptides for dermal and hair-follicle research, with copper content reported per lot.
2 products →This category splits into two mechanistically distinct groups that are frequently conflated. GHRH analogues — sermorelin, tesamorelin, CJC-1295 — act at the growth-hormone-releasing hormone receptor. Secretagogues such as ipamorelin and MK-677 act instead at the ghrelin receptor (GHS-R1a). The distinction is the reason the two are studied together in the literature: research examines whether the combination produces a different secretory profile than either class alone.
IGF-1 LR3 belongs to neither group. It is a modified insulin-like growth factor with reduced binding-protein affinity, studied downstream of growth hormone signalling rather than upstream of it, and is included here because the research questions connect.
Structural detail is published on every compound page in this category: full amino acid sequence where the compound is a peptide, CAS number, molecular formula and molar mass. Each lot carries an independent certificate showing measured purity and measured content, linked to the batch code on the vial. Supplied strictly as laboratory research materials.
In this category: Ipamorelin · CJC-1295 · Sermorelin · Tesamorelin · IGF-1 LR3
They act at different receptors. Sermorelin, CJC-1295 and tesamorelin are analogues of growth hormone-releasing hormone and are characterised as acting at the GHRH receptor. Ipamorelin is a ghrelin receptor agonist, which is a separate pathway. Much of the published work studies the two classes together for that reason, and the blends in this catalogue pair one of each.
The Drug Affinity Complex is a modification that extends the molecule’s circulating half-life substantially. The two forms therefore have different pharmacokinetic profiles in the published literature and are studied as distinct compounds. This store lists the No-DAC form, sometimes referred to in the literature as modified GRF (1-29).
It is downstream of one. IGF-1 is the mediator through which much of growth hormone’s activity is described, and LR3 is a long-acting analogue with a substitution and an N-terminal extension that reduce its binding to IGF-binding proteins. It is grouped here because the research literature treats the axis as one subject.
An independent certificate for the exact lot shipped, showing HPLC purity, measured content against the labelled amount and the issuing laboratory’s test date. Both the purity and the mass figures are published whichever way they fall — a supplier that publishes only the flattering number has answered the easier question.
All products are supplied for in vitro and laboratory research purposes only.
